Amyloid-A peptide (AA) plays an essential pathophysiologic role in Alzheimer disease, and elevation of luteinizing hormone (LH) levels during aging has been implicated in its pathogenesis. To assess the effect of LH receptor deficiency on AA accumulation, we generated a bigenic mouse model, APPsw + /Lhr j/j , which expresses human amyloid precursor protein (APPsw) in the background of LH receptor (Lhr) knockout. Genetic ablation of Lhr resulted in a significant decrease in the number of AA plaques and protein content in the hippocampus and cerebral cortex in both male and female mice. Accordingly, several AA deposition-related neuropathologic features and functionally relevant molecules were markedly improved, including decreased astrogliosis, reductions of elevated phosphorylated tau, c-fos, >7-nicotinic acetylcholine receptor, and restoration of the altered neuropeptide Y receptors Y1 and Y2. Diminution of AA accumulation in the absence of LH receptor supports the contention that dysregulation of LH may impact the pathogenesis of Alzheimer disease. The APPsw + /Lhr j/j mouse may be a useful tool for advancing understanding of the role of LH-mediated events in Alzheimer disease and a model in which to test therapeutic interventions.
INTRODUCTION
Alzheimer disease (AD) is an age-associated disorder marked by cognitive decline coupled with distinct neuropathologic hallmarks that include extracellular senile plaques and intracellular neurofibrillary tangles (NFTs) (1, 2) . Although most cases of AD are sporadic, familial and sporadic AD cases have similar clinical manifestations and neuropathologic features. Amyloid-A peptide (AA) is derived from enzymatically processed fragments of amyloid precursor protein (APP) by A-and F-secretase complexes (3Y5) and is the principal constituent of senile plaques. The overproduction, accumulation, and aggregation of AA in plaque cores are characteristic of AD (6, 7) .
Overwhelming evidence obtained from in vitro and in vivo studies using neuronal cell lines and APP transgenic animal models indicates that AA is a primary cytotoxic molecule in the brain and plays a central role in AD pathogenesis (8Y10). A cascade initiated by AA is thought to result in aberrant phosphorylation of tau protein and its subsequent aggregation to form NFTs (11) . Decline in learning and memory functions correlate with progressive AA deposition and NFT formation in the limbic and associated cortices during the course of AD (1, 2) . Cognitive impairment also correlates with astrogliosis, neuritic dystrophy, synaptic deficits, and imbalance of neuronal network activity. Additionally, there are alterations of numerous functionally relevant molecules, notably the immediate early gene product c-fos, the neurotransmitter neuropeptide Y (NPY), and neurotransmitter receptors neuropeptide Y receptor Y1 (NPY1R), neuropeptide Y receptor Y2 (NPY2R), and >7-nicotinic acetylcholine receptor (>7-nAChR) (12Y19).
Luteinizing hormone (LH) and its homolog, human chorionic gonadotropin (hCG), are heterodimeric glycoprotein hormones that bind to a common G-proteinYcoupled receptor often called LH/hCG receptor. Increased gonadal steroidogenesis is a hallmark endocrine function of LH and hCG. The synthesis and secretion of LH are subject to both positive and negative feedback regulation by gonadal steroids, estrogens, and androgens. The major endocrine changes of the hypothalamic-pituitary-gonadal axis during aging are decreased sex steroid hormones due to aging of the ovary and testis. This results in chronic LH elevation (20) .
Both hormonal alterations of the hypothalamicpituitary-gonadal axis and the incidence of AD increase with age, suggesting that there may be a relationship between these processes. Estrogens have received considerable attention in the last decade for their effects on age-related neurodegenerative changes and cognitive decline (21, 22) . Clinical trials, however, have not demonstrated that estrogens improve AD symptoms, and whether there is a role for estrogens in the prevention of AD remains uncertain (23) . There are several lines of circumstantial evidence suggesting that LH may be a factor relevant to the pathogenesis of AD. First, serum LH and hCG concentrations correlate with the incidence of AD. The increase in LH after menopause/andropause is higher and occurs earlier in women who are more susceptible to AD than men. There are 2-fold higher serum LH levels in individuals with AD than age-matched controls (24, 25) . Second, several brain regions in various species, including humans, express functional LH/hCG receptors (26, 27) . In particular, the hippocampus (HP) contains the highest density of LH receptor (26) . Recent genetic analysis demonstrated that an Lhr variant reduced the risk of AD in male apolipoprotein E carriers (28) . Third, LH and hCG can cross the blood-brain barrier from the peripheral circulation, and it is possible that they may be produced within the brain (27) . Fourth, LH has been shown to alter APP processing toward the amyloidogenic pathway in vitro (29) . Administration of hCG or pharmacologic suppression of LH reduced AA accumulation in rat and mouse brains (30, 31) . A recent study also demonstrated that serum LH levels were positively correlated with AA levels in elderly men (32) .
Because AA is believed to be the key molecule that triggers many aspects of AD pathogenesis, we sought to establish an additional link between neuronal LH actions and AD. We investigated whether the effects of genetic ablation of Lhr can affect amyloidosis and the AA-linked biochemical and neurologic alterations of AD in a mouse model. We provide in vivo evidence that genetic ablation of LH receptors from a human APP transgenic mouse results in a significant reduction of AA load in the brain and improvement of several AA-relevant abnormalities, including increased phospho-tau protein (P-tau), astrogliosis, and an imbalance of excitatory and inhibitory networks in the hippocampus (HP) and cerebral cortex (CX).
MATERIALS AND METHODS

Animals
Bigenic animals were produced by cross-breeding Tg (HuAPP695.K670N-M671L) 2576 mice with Lhr knockout (KO) heterozygotes. Tg (HuAPP695.K670N-M671L) 2576 mouse is a well-characterized transgenic model that expresses human APP-695 with the BSwedish[ mutation and manifests age-dependent cognitive alterations and development of amyloid deposition, similar to human AD (33) . In the present study, we adopted the name APPsw + , as described elsewhere for this mouse model (34) . APPsw + mice that were originally generated by Hsiao et al (33) were purchased from Taconic (Hudson, NY). Lhr KO mice were previously established in our laboratory (35) . The zygosities of these animals were determined by polymerase chain reaction (PCR) of genomic DNA isolated from mouse tails using the primer sets listed in 
Immunohistochemistry and Immunofluorescence
Six-micrometer-thick sagittal sections were cut from the paraffin-embedded blocks and were sequentially treated for 10 minutes with 88% formic acid (Fisher Scientific) and for 1 hour with 2% blocking serum in phosphate-buffered saline. They were then incubated overnight at 4-C with 1:300 dilution of mouse anti-AA monoclonal antibody (Clone 4G8, which recognizes AAx-42, including the P3 fragment [36] , or 9C4, which recognizes AAx-43; Millipore, Temecula, CA), 1:150 dilution of rabbit anti-NPY antibody (Immunostar, Hudson, WI), 1:150 dilution of rabbit antiYP-tau antibody (phosphothreonine 205; Millipore), and 1:300 dilution of rabbit antiYglial fibrillary acidic protein (GFAP) antibody (Sigma, St. Louis, MO), respectively. Immunostaining of AA was detected by an avidin-biotin immunoperoxidase complex method using a kit purchased from Vector Laboratories (Burlingame, CA).
Immunostaining of NPY was detected by incubation of 1:100 diluted fluorescein isothiocyanateYlabeled goat antirabbit immunoglobulin G. The double immunofluorescent labeling was performed by incubation of the sections together with primary antibodies against AA and GFAP or AA and P-tau, and then together with both fluorescein isothiocyanateY labeled goat anti-rabbit and Texas RedYlabeled goat antimouse immunoglobulin G (Jackson Immunoresearch, Inc., West Grove, PA). The slides were covered with Ultracruz mounting medium (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), which contains 4 ¶,6-diamidino-2-phenylindole blue fluorescence for visualization of cell nuclei. 
Quantification of Amyloid Plaque Load
The numbers of amyloid plaques in the entire areas of HP and CX were quantitatively analyzed using an imaging application software (Microsuite version 5; Olympus Soft Imaging Solution Corp., Lakewood, CO). An average of 5 sections from each animal was used for counting. The results were expressed as number of amyloid plaques per square micrometer of HP or CX. Based on the appearances of amyloid deposition, the plaques were classified as either Bdiffuse,[ in which the immunostaining of the plaque does not have a clear border, or Bcored,[ in which there was intense immunostaining and a relatively sharp border (37) .
Semiquantitative Reverse-TranscriptaseYPCR
Total RNA of the HP and CX was isolated using Trizol reagent (Invitrogen, Carlsbad, CA), and 2 Kg of isolated RNA was reverse-transcribed into cDNA using avian myeloblastosis virus reverse transcriptase (Promega Corp., Madison, WI) and random oligonucleotide hexamers (Invitrogen). The PCR primers listed in Table 2 were designed from the sequences obtained from Genbank using Vector NTI 9.0 program (InforMax, Frederick, MD) and synthesized by Operon Technologies (Alameda, CA). All primers were designed to amplify products that covered at least 1 or more exons. Then, PCR reactions were performed with primer sets of a target gene and the ribosomal protein large subunit 19 (Rpl19), a housekeeping gene as an internal control for cDNA quantity and quality. Optimal conditions and PCR cycle numbers for each target gene (Table 2) were predetermined to ensure that coamplification was within the linear range. Each PCR cycle consisted of denaturation for 45 seconds at 94-C, annealing for 1 minute at 57-C, and extension for 1 minute at 72-C. The amplified products were electrophoresed in 1.5% agarose gels, stained with ethidium bromide, and analyzed using TotalLab Version 2.01 (Nonlinear USA, Durham, NC) image analysis software; ratios of target gene to housekeeping gene Rpl19 were then calculated. Representative pictures and the fold changes (mean T standard error of mean) calculated from 3 independent experiments are presented. All reactions were repeated 2 to 3 times for each genotype.
Western Blotting
The HP and CX were homogenized for 30 seconds at 4-C in a lysis buffer (pH 7.4) composed of 50 mmol/L of Tris-HCl, 150 mmol/L of NaCl, 1% Triton X-100, 0.25% sodium deoxycholate, 1 mmol/L of EDTA, 1 mmol/L of Na 3 VO 4, 1 mmol/L of NaF, and 150 KL/mL of protease inhibitor mixture (Roche Applied Science, Indianapolis, IN). The protein concentrations in the homogenates were determined using the Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA). The homogenates were separated into pellets and supernatants by centrifugation at 12,000 Â g for 15 minutes at 4-C.
The pellets were extracted with 70% formic acid for determination of AA levels according to the procedure described by Kawarabayashi et al (38) . Briefly, the formic acid fractions were evaporated using an N-EVAP nitrogen evaporator (Organomation Associates, Inc., Berlin, MA) and dissolved in dimethyl sulfoxide. The dissolved fractions were then separated on 16% Tricine sodium dodecyl sulfateY polyacrylamide gel electrophoresis gels and electrotransferred to nitrocellulose membranes (Bio-Rad). Membranes were then incubated overnight at 4-C with 1:1000 dilution of 4G8 monoclonal antibody for detection of AA. For detections of P-tau, >7-nAChR, NPY1R, NPY2R, and c-fos, an equal amount of proteins in the supernatants was loaded, separated on discontinuous 10% sodium dodecyl sulfateYpolyacrylamide gel electrophoresis gels under reducing conditions, and electrotransferred onto 0. detection system (Amersham Pharmacia Biotech, Inc., Piscataway, NJ). All membranes were reblotted with either A-actin or A-tubulin antibody, which served as a loading control. The molecular sizes of the proteins were determined by running protein markers in an adjacent lane. Densitometric analysis of the specific bands using TotalLab Version 2.01 image analysis software normalized to A-actin or A-tubulin. Representative blots and the fold changes (mean T standard error of mean) calculated from 3 independent experiments are presented. All experiments were repeated 2 to 3 times for each genotype.
Statistical Analysis
All results were analyzed by one-way ANOVA and Student-Newman-Keuls using an Instat version 3.06 program (Graphpad Software, San Diego, CA). A p value less than 0.05 was considered significant. (Fig. 1A) . Lhr KO did not change the AA deposition pattern, but there were fewer AA plaques in the HP and CX of both female and male APPsw + /Lhr j/j mice compared with their APPsw + /Lhr +/+ littermates (Fig. 1A) . The total plaque numbers in both regions were significantly reduced in APPsw + /Lhr j/j mice (Fig. 1B) . When cored and diffuse plaques were counted separately, most of the plaques were cored, and Lhr KO led to a pronounced decrease in their numbers. The diffuse-type plaques exhibited a decreased trend, and they did not reach statistical significance except for those in the CX in female APPsw + /Lhr j/j mice (Fig. 1B) . Western blot analysis indicated that HP and CX levels of 4 kDa AA protein were markedly decreased in both female and male APPsw + /Lhr j/j mice compared with APPsw + /Lhr +/+ littermates (Fig. 1C) 
RESULTS
Lhr
Effects of Lhr Deficiency on Excitatory and Inhibitory Networks
Western blots were performed to determine whether the change of AA accumulation in APPsw + /Lhr j/j mice affects the protein levels of phosphorylated-tau, >7-nAChR, and c-fos in the HP and CX. Levels of P-tau (Fig. 3A) , >7-nAChR (Fig. 3B) , and c-fos (Fig. 3C) were remarkably elevated in both the HP and CX of APPsw + /Lhr +/+ mice compared with APPsw j /Lhr +/+ littermates. Lhr KO resulted in a significant decrease, although they did not completely return to the levels of APPsw The mRNA levels of Npy1r in both the HP and CX of APPsw + /Lhr +/+ male mice were noticeably lower than in the APPsw j /Lhr +/+ counterparts (Fig. 4A) , whereas female mice did not display significant changes among the genotypes. The decreased Npy1r mRNA levels in male mice were restored by genetic inactivation of Lhr (Fig. 4A) . In contrast, the mRNA levels of Npy2r were markedly increased in APPsw (Fig. 4A) . Interestingly, this phenomenon was observed in the HP and CX of female but not male mice in any genotype (Fig. 4A) . Western blot analysis also demonstrated that the NPY1R protein levels were reduced in the HP and CX of APPsw + /Lhr +/+ male mice. In Lhr-deficient male mice, the levels were comparable with those observed in APPsw j /Lhr +/+ male mice (Fig. 4B) . The protein levels of NPY2R, on the other hand, were elevated in the HP and CX of APPsw + /Lhr +/+ female mice and returned to wild-type levels in Lhr-deficient female mice (Fig. 4B) .
DISCUSSION
Transgenic mice that overexpress human APP display histopathologic features that parallel those of AD (21, 40, 41) . Because aging-associated LH dysregulation may be involved in AD pathogenesis, we sought to determine whether AA deposition was affected in Lhr-deficient human APP transgenic mice. We found that genetic inactivation of Lhr led to a reduction of AA plaques in the HP and CX, with a much more pronounced reduction in female than in male mice. According to the AA-initiated hypothesis of AD pathogenesis, AA first induces aberrant hyperphosphorylation of tau protein and then formation of paired helical filaments that constitute NFTs (11, 42, 43) . As in previous reports (33, 40), we did not observe typical NFTs in the brains of APPsw + transgenic mice. We determined, however, that the phosphorylated tau content was markedly elevated over controls in APPsw + /Lhr +/+ mice, and that a lack of LH was associated with a reduction in the increased phosphorylated tau level. Therefore, we postulate that abolishing LH signaling in the brain may alleviate not only the formation of AA plaques but also of NFTs and thus may improve cognitive impairment. Indeed, Casadesus et al (44) demonstrated that, although HP-associated cognitive test results of Lhr null mice was not distinguishable from that of wild-type animals, transgenic mice with a chronic elevation of LH displayed poor cognitive performances. Moreover, a gonadotropin-releasing hormone agonist suppressed LH levels and markedly reduced AA burden in the HP with a concurrent improvement in HP-associated cognitive performance in APP transgenic mice (30) .
The mechanism by which Lhr KO causes a dramatic reduction of AA accumulation in the brains of APPsw + mice is not clear. AA is a product of the proteolytic processing of APP by A-secretase (BACE1) and F-secretase (5, 45). Fsecretase activity is mediated by a multiprotein complex consisting of presenilins (PS1 and PS2), anterior pharynx defective 1A homolog, anterior pharynx defective 1B homolog, presenilin enhancer 2 homolog, and nicastrin (3, 4) . In addition, Ranbinding protein 9 and lipoprotein receptorYrelated protein interact with APP and BACE1 to enhance AA generation (46) . Degradation and clearance of AA in the brain are thought to depend primarily on insulin-degrading enzyme and neprilysin (47, 48) . We found that the mRNA levels of BACE1, PS1, PS2, presenilin enhancer 2 homolog, lipoprotein receptorYrelated protein, insulin-degrading enzyme, and neprilysin in the HP and CX did not differ significantly among APPsw AA production and catabolism in the brain require further investigation. Astrogliosis is a prominent neuropathologic feature of AD, but it is not clear whether astrogliosis is induced by AA or if it precedes the appearance of AA plaque formation (12, 16, 41, 49Y51) . We found that reactive astrocytes were exclusively confined to the regions surrounding AA plaques. No reactive astrocytes were detected in areas without AA deposition or in the brains of wild-type animals at the same age. The density of reactive astrocytes surrounding cored AA plaques in APPsw + /Lhr j/j mice decreased along with the reduction of AA plaques, suggesting that astrogliosis is a response to AA accumulation. Indeed, DeWitt et al (12) reported that incubation of glial cells with AA triggered reactive astrogliosis in vitro. On the other hand, astrogliosis inhibits microglial phagocytosis, thereby inhibiting AA removal (12, 52, 53) . Our results raise the possibility that the decrease in cored plaques could be secondary to decreased astrogliosis, that is, the reduced inhibition of the phagocytotic activity of microglia would result in increased removal of the plaques.
Neurons and astrocytes in the HP and CX contain c-fos and >7-nAChR (16, 54, 55) , and there is in vitro and in vivo evidence that AA stimulates the expression of c-fos and >7-nAChR (13Y15). Overexpression of c-fos may be a mechanism by which AA triggers programmed cell death in the brain (56) . >7-nAChR has an extremely high affinity to AA; that is, cells that overexpress this receptor exhibited rapid binding, internalization, and accumulation of exogenous AA (55) . Therefore, accumulation of AA in the brain might be escalated by inducing overexpression of >7-nAChR, which eventually would exacerbate aberrant tau phosphorylation, brain cell death, and memory impairment. Because amelioration of AA burden in APPsw + /Lhr j/j mice concomitantly lowered the elevated c-fos and >7-nAChR proteins, it is conceivable that blockade of LH actions in the brain might improve the aspects of brain pathophysiology in AD that are mediated through these molecules.
Disruption of the balance between excitatory and inhibitory neuronal activities is also characteristic of AD (17) . Neuropeptide Y receptor Y1 exerts a weak excitatory activity, and NPY2R mediates a potent inhibitory activity of NPY (57) . The NPY network is involved in learning and memory functions (58, 59) , and imbalanced NPY network activity has also been implicated with an increased incidence of unprovoked seizures in AD (60, 61) . We found that Npy expression was not significantly different among any of the 3 mouse genotypes studied, whereas NPY receptors exhibited gender-specific alterations. In females, NPY2R levels were elevated with no change in NPY1R. In contrast, NPY1R levels were reduced with no change in NPY2R in males. Nevertheless, both changes were attenuated in Lhr KO animals. Although it is not yet clear how AA perturbs NY1R and NPY2R differently in females and males, our results indicate that genetic removal of Lhr restored the altered pathophysiology. The differences between our study and previous reports showing AA-mediated diminishing of NPY and NPY1R and elevation of NPY2R might be due to the use of different APP transgenic animal models and/or different age and sex of the mice (18, 62) . In summary, the APPsw + /Lhr j/j animal model provides evidence that reduction of AA accumulation in the absence of neuronal LH action mitigates astrogliosis; corrects aberrant phospho-tau, c-fos, and >7-nAChR protein levels; and seems to restore balance to the NPY network. These findings suggest that chronic elevation of LH levels may promote AA plaque formation and thus hasten AD progression. This bigenic APPsw + /Lhr j/j mouse model provides a useful tool to further our understanding of the role of LHmediated events in AD pathogenesis as well as a potential means to test therapeutic interventions in AD.
